Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Invasive pneumococcal disease in Australia, 2002.

Paul Roche1, Vicki Krause, Ross Andrews

  • 1Surveillance and Epidemiology Section, Department of Health and Ageing, Canberra, Australian Capital Territory. paul.roche@health.gov.au

Communicable Diseases Intelligence Quarterly Report
|October 29, 2004
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomized, Double-Blind, Placebo-Controlled First-in-Human Trial of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem Helix.

The Journal of infectious diseases·2026
Same author

Standardizing Dental Hygiene Education: Faculty and Student Perceptions on Calibration Techniques.

Journal of dental education·2026
Same author

Psychological Screening and Support for Patients Enrolled in Early-Phase Cancer Clinical Trials and the Possible Barriers: A Real-World Tertiary Center Implementation Study.

Psycho-oncology·2026
Same author

Pharmacokinetics of Asciminib 200 mg in the Presence of a Strong CYP3A4 Inducer, Phenytoin, in Healthy Participants.

Clinical pharmacokinetics·2026
Same author

Expansion cohorts in phase 1 oncology trials: a systematic review of their design, implementation and outcomes.

British journal of cancer·2026
Same author

Ligand non-competitive GITR antibody prevents formation of the obligatory signal-triggering GITRL: GITR stoichiometry.

Scientific reports·2025

Invasive pneumococcal disease (IPD) affected 2,271 Australians in 2002, particularly children and Indigenous populations. Pneumonia and bacteraemia were common, with a 9.2% fatality rate, highlighting the need for vaccination strategies.

Area of Science:

  • * Public Health and Epidemiology
  • * Infectious Diseases
  • * Vaccinology

Background:

  • * In 2002, 2,271 cases of invasive pneumococcal disease (IPD) were reported in Australia.
  • * Notification rates varied geographically, with the highest incidence in northern regions.
  • * Children under five years old had the highest IPD rates (57.3 per 100,000 population).

Purpose of the Study:

  • * To analyze the epidemiology of invasive pneumococcal disease in Australia during 2002.
  • * To compare IPD rates and characteristics between Indigenous and non-Indigenous populations.
  • * To assess the serotype distribution of pneumococcal isolates in relation to available vaccines.

Main Methods:

  • * Utilized enhanced surveillance data from all Australian states and territories for 2002.

Related Experiment Videos

  • * Collected data on 1,929 (85%) of all notified IPD cases.
  • * Analyzed clinical presentations, risk factors, and serotype information of pneumococcal isolates.

    • Main Results:

    • * Indigenous Australians experienced IPD at 2.7 times the rate of non-Indigenous Australians.
    • * Pneumonia (44%) and bacteraemia (35%) were the most common clinical presentations.
    • * The overall case fatality rate for IPD was 9.2%, with 175 deaths.
    • * Recognized risk factors were present in 42% of cases.
    • * Serotypes included in the 7-valent conjugate vaccine (75%) and 23-valent polysaccharide vaccine (93%) were predominant.
    • * Non-vaccine serotypes were more frequent in Indigenous children and adults.

    Conclusions:

    • * Invasive pneumococcal disease poses a significant public health burden in Australia, disproportionately affecting Indigenous populations and young children.
    • * The majority of circulating pneumococcal serotypes are covered by existing vaccines, but non-vaccine serotypes are a concern, particularly in Indigenous communities.
    • * Targeted public health interventions and vaccination strategies are crucial to reduce IPD incidence and mortality, especially among vulnerable groups.